Lantern Pharma - LTRN Net earnings per share for the last 12 months

Lantern Pharma Inc (LTRN) - corporate logo

Lantern Pharma Inc. (LTRN) is an IT-biotech startup developing AI-powered software to accelerate the discovery of anti-tumor drugs within the B2B segment. This price chart illustrates the EPS TTM trend, which currently stands at 9.80. Business growth is driven by the recruitment of leading bioinformaticians and engineers. The integration of digital systems with medical data enables the company to identify rare biomarkers for highly precise lung cancer therapy.

Lantern Pharma (LTRN): Earnings per share for the last twelve months from 02/11/2024 to 11/17/2026

Lantern Pharma Inc. - analytical breakdowns and key metrics (LTRN)

- share price and consensus valuation forecast:
Initial company analysis:Lantern Pharma Inc., LTRN
Flagship merchandise of Lantern

Year-over-year EPS growth (TTM) measures the change in net income per share over a rolling year, reflecting the efficiency of the RADR AI platform in monetizing cancer biomarkers. The current value of 9.80 on this daily EPS TTM chart allows for a real-time assessment of the pricing power of Lantern Pharma Inc. (LTRN), although the indicator's peak points often signal a correction risk during a shift in the market cycle.